Renovaro BioSciences Congratulates GEDiCube on New Joint Effort Clinical Trials
LOS ANGELES, CA - (NewMediaWire) - September 6, 2023 - (InvestorBrandNetwork via NewMediaWire) - IBN, a multifaceted financial news, content creation and publishing company, is utilized by both public and private companies to optimize investor awareness and recognition.
Renovaro BioSciences Inc. (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, released a statement congratulating GEDiCube on its joint effort to accelerate early diagnosis of cancer in clinical trials. GEDiCube is partnering with NVIDIA Inception on clinical trials focused on advancing a unique platform for early cancer detection. The platform combines techniques for boosting the body's natural tumor-fighting mechanisms with artificial intelligence and machine learning technology. "This is a natural fit for GEDiCube that will help us in our mission to detect cancer at its earliest stage," said GEDiCube CEO Craig Rhodes in the press release. "NVIDIA's advanced medical imaging capabilities with GEDiCube's existing multiomic AI system will help create an algorithm that pulls from both the imaging and omic modals. This will help our scientists understand the radiology and pathology imaging data alongside multiomic data, thus enabling a better analysis of cancer."
To view the full press releases, visit https://ibn.fm/ZGDRj and https://ibn.fm/zw9sS
About Renovaro BioSciences Inc.
Renovaro BioSciences is an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy. The company's advanced cell, gene and immunotherapy techniques are designed to reinvigorate the body's natural tumor-fighting mechanisms. For more information about the company, visit www.RenovaroBio.com.
NOTE TO INVESTORS: The latest news and updates relating to RENB are available in the company's newsroom at https://ibn.fm/RENB
About IBN
IBN has introduced 50+ distinct investor-focused brands over the last 15+ years and has leveraged these unique brands to amass a collective audience of millions of social media followers. In conjunction with 5,000+ syndication partnerships, IBN's broad-based investor-facing brands help fulfill the diverse demands and needs of our rapidly growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, harnessing the energy and experience of our team of specialized experts to exceed the expectations of each of our client-partners.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
Corporate Communications
IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com
